Health Condition 1: E282- Polycystic ovarian syndrome
Conditions
Interventions
Intervention1: Metformin HCl and Myo-inositol: Fixed Dose Combination (FDC) of Metformin HCl(SR) 500 mg and Myo-inositol 600 mg. 1 Tablet BID for 24 weeks.
Control Intervention1: Metforminin: Metformi
Sponsors
Eris Lifesciences Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Adult female subjects 18 to40 (both inclusive) years of age. 2.Subject diagnosed of polycystic ovary syndrome (PCOS), according to Rotterdam Criteria, if she has 2 of the following 3 manifestations: •Hyperandrogenism (defined by elevated free testosterone concentration; or Ferriman-Gallwey Score of greater than or equal to 8). •Disturbed ovulatory function with chronic oligomenorrhea (cycles of > 35 days less than nine cycles per year), or amenorrhea (cycle length > 12 weeks) after negative screening pregnancy test. •Polycystic ovary as shown by transvaginal ultrasonography (TVUS). NOTE: As per FIGO recommendation to characterize menstrual irregularities and accordingly, those subjects who are having menstrual cycle of more than 38 days will be included in the study. 3.Subjects with established insulin resistance (by using HOMA IR model, which can be supported by clinical evidences of BMI more than 23 or impaired GTT or cutaneous manifestations like acanthosisnigricans etc.) 4.Subject is willing and able to take oral medications. 5.Subject is willing to continue with regular follow-up as required for the study. 6.Subject willing to observe barrier contraception (oral contraceptives or any other hormonal medications not to be consumed) during the study period.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women (urinary pregnancy test will be applied at screening). 2.Subject with previous medical history (either laboratory or clinical) or currently having any of the following conditions: Cushings syndrome, late onset of congenital adrenal hyperplasia, androgen-secreting tumours, uncontrolled thyroid disease, hyperprolactinemia or any other hormonal dysfunction. 3.Subject with history or current status of diabetes mellitus, uncontrolled hypertension, symptomatic cardiovascular diseases. 4.Subject with any acute or chronic infections at the time of screening. 5.Subject with history of malignancies. 6.Subject with known history of gynaecological surgery. 7.Subject having impaired renal or liver function at the time of screening. 8.Subject who is currently on a medically-assisted weight loss program with medication or surgical procedures. 9.Subject currently having laparoscopic ovarian diathermy (LOD). 10.Subject who is willing to or currently undergoing in vitro fertilization (IVF), or considering participation in any artificial reproduction techniques (ART) program. 11.Subject who has received or is currently receiving following medication within past 3months of screening: clomiphene citrate; insulin sensitizers like Metformin and thiazolidinediones; aromatase inhibitors like anastrozole, letrozole; glucocorticoids; gonadotropins; gonadotropin-releasing hormone agonists (GnRHa); hormonal contraceptives; antiandrogens like spironolactone, cyproterone acetate (CPA), and flutamide; anti-obesity drugs; or any traditional or herbal medicines. 12.Known history or current use of alcohol, smoker or tobacco user, or Subject with unstable mental illness. 13.Subject is participating or has participated in any other clinical trial within last 30 days prior to screening. 14.In the opinion of the investigator, the Subject is not eligible to participate or may not complythe study procedures. 15.Subject having contraindication or known allergy to any of the study treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Percentage of subjects with improvement in Insulin resistance (HOMA-IR) at 24 weeks of treatment in FDC arm vs. Metformin arm. 2. Percentage of subjects with improvement in menstrual cycle disturbance at 12 and 24 weeks of treatment in FDC arm vs. Metformin arm. (accordance with FIGO recommendations)Timepoint: 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in serum testosterone levels after 24 weeks of treatment Changes in systolic and diastolic blood pressure after 24 weeks of treatment Changes Hip-Waist ratio after 24 weeks of treatment Changes in BMI after 24 weeks of treatment Changes in lipid levels (TC, TG, LDL and HDL) after 24 weeks of treatment Changes in Estradiol/Progesterone/LH/FSH/SHBGafter 24 weeks of treatmentTimepoint: 24 weeks | — |
Countries
India
Contacts
Public ContactDr Milan Satia
Ethicare Clinical Trial Services
Outcome results
None listed